左甲状腺素剂量与甲状腺功能减退治疗不达标的纵向真实世界研究
这项6个月纵向真实世界研究纳入4449例接受左甲状腺素(LT4)治疗的成人,按LT4剂量分组(≤50、51-100、101-150、>150 µg),分析正常TSH后6个月内出现不达标治疗(TSH超出年龄调整正常范围或0.1-10.0 mIU/L)与LT4剂量的关联。结果显示LT4剂量与TSH超出年龄调整范围呈剂量依赖性关系(OR分别为1.98、3.39、5.65,P<0.001),>150 µg组至少一次TSH超出范围的发生率超过45%。
要点
- LT4剂量与6个月内TSH超出年龄调整范围呈剂量依赖性关联。
- LT4>150 µg组至少一次TSH超出范围的发生率超过45%。
- 高剂量LT4治疗的复杂患者可能需增加TSH监测频率。
核心结论
- 在6个月研究期内,LT4剂量与不达标治疗之间存在剂量依赖性关系。
- 接受高剂量LT4的医学复杂患者增加TSH监测可能有益,尤其是有不达标治疗史者。
研究设计与样本
- 纵向真实世界研究,纳入4449例接受LT4治疗的成人,研究期6个月。
- 所有患者在研究期内至少有2次TSH检测,间隔至少30天。
- 按LT4剂量分组(≤50、51-100、101-150、>150 µg)作为主要暴露。
- 采用重复测量(广义估计方程)和事件发生时间(Cox比例风险模型)方法分析,并绘制Kaplan-Meier曲线。
主要发现
- 整个人群中至少一次TSH超出范围的发生率接近25%,LT4>150 µg组超过45%。
- 重复测量分析中,LT4剂量与TSH超出年龄调整范围呈剂量依赖性关系(OR:1.98、3.39、5.65,分别对应51-100、101-150、>150 µg,P<0.001)。
- 以TSH超出0.1-10.0 mIU/L为结局时结果相似。
- 事件发生时间分析中,风险比分别为1.58、2.73、3.08(P<0.001)。
临床怎么用
- 对使用高剂量LT4的医学复杂患者,可考虑增加TSH监测频率。
- 尤其应关注有治疗不达标史的LT4治疗患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Suboptimal treatment of hypothyroidism with levothyroxine (LT4) is common and associated with adverse cardiovascular outcomes. Patients treated with LT4 doses >100 µg may be at increased risk of under- and overtreatment and therefore may benefit from more frequent thyroid stimulating hormone (TSH) surveillance. Our study aim was to determine the association between LT4 dose and the occurrence of suboptimal treatment within 6 months of a normal TSH value. METHODS: A total of 4449 LT4-treated adults were included in a 6-month longitudinal study. All included patients were required to have at least 2 TSH collections over the study period at least 30 days apart. Patients were grouped according to LT4 dose (≤50, 51-100, 101-150, and >150 µg), which served as the primary exposure. Outcomes included the occurrence of TSH values outside an age-adjusted normal range and a wide range (0.1-10.0 mIU/L). Model covariates included sociodemographics, index TSH value, and a range of codiagnoses and comedications that were prevalent in the population and/or known to impact LT4 treatment. Longitudinal data were analyzed using both repeated measures (generalized estimating equations) and time-to-event (Cox proportional hazards models) methodologies. Kaplan-Meier curves were plotted to examine the incidence of out-of-range TSH values stratified by LT4 dose class. RESULTS: The incidence of at least one out-of-range TSH value approached 25% across the entire population and exceeded 45% in the LT4 > 150 µg group. In the repeated measures analysis, a dose-dependent relationship between LT4 dose and the occurrence of TSH outside the age-adjusted range (OR: 1.98, 3.39, and 5.65 for LT4 doses of 51-100, 101-150, and >150 µg, respectively, p-values <0.001). Results were similar when the outcome was defined as a TSH outside 0.1-10.0 mIU/L. In the time-to-event analysis, the hazard ratios were 1.58, 2.73, and 3.08, respectively (p-values <0.001). CONCLUSIONS: We identified a dose-dependent relationship between LT4 dose and suboptimal treatment over a 6-month study period. It may be beneficial for medically complex patients taking high doses of LT4 to increase TSH surveillance, in particular for those with a history of suboptimal treatment.
引用
- Ettleson MD, Wan W, Laiteerapong N, et al. A Longitudinal, Real-World Study of the Relationship between Levothyroxine Dose and Suboptimal Hypothyroidism Treatment. Thyroid. 2026. PMID: 42308153. doi:10.1177/10507256261462468
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。